These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18462543)

  • 21. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Menkes DB; Woodall AA
    N Z Bioeth J; 2003 Oct; 4(3):22, 24-5. PubMed ID: 15597480
    [No Abstract]   [Full Text] [Related]  

  • 22. Developing drugs for the developing world: an economic, legal, moral, and political dilemma.
    Resnik DB
    Dev World Bioeth; 2001 May; 1(1):11-32. PubMed ID: 12870505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Democracy unleashed--unpacking the tooth fairy in drug industry R&D.
    Ozdemir V; Williams-Jones B
    Nat Biotechnol; 2006 Nov; 24(11):1324-6; author reply 1326-7. PubMed ID: 17093467
    [No Abstract]   [Full Text] [Related]  

  • 24. Three reasons why a global market in pharmaceutical products is inherently unjust.
    Holm S
    J Soc Philos; 2000; 31(4):391-400. PubMed ID: 15069945
    [No Abstract]   [Full Text] [Related]  

  • 25. Population aging and international development: addressing competing claims of distributive justice.
    Engelman M; Johnson S
    Dev World Bioeth; 2007 Apr; 7(1):8-18. PubMed ID: 17355327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experiments in social responsibility.
    Herrling P
    Nature; 2006 Jan; 439(7074):267-8. PubMed ID: 16421547
    [No Abstract]   [Full Text] [Related]  

  • 27. Introduction: ethical responsibilities regarding drugs, patents, and health.
    Ryan MP
    Bus Ethics Q; 2005 Oct; 15(4):543-7. PubMed ID: 16358441
    [No Abstract]   [Full Text] [Related]  

  • 28. [Comments on the editorial "The health sector and the perpetual murkiness in the relations between the medical profession and the drug industry" ].
    Oteo Ochoa LA
    Rev Calid Asist; 2009 Aug; 24(4):178-81. PubMed ID: 19647681
    [No Abstract]   [Full Text] [Related]  

  • 29. Your money or your life: a new variation on the Heinz Dilemma.
    Thompson RE
    Physician Exec; 2004; 30(1):58-61. PubMed ID: 14983708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug industry in India is threatened by free trade agreement].
    Jeppsson A
    Lakartidningen; 2009 Oct 7-13; 106(41):2589. PubMed ID: 19927922
    [No Abstract]   [Full Text] [Related]  

  • 31. Does the pharmaceutical sector have a coresponsibility for the human right to health?
    Schroeder D
    Camb Q Healthc Ethics; 2011 Apr; 20(2):298-308. PubMed ID: 21435305
    [No Abstract]   [Full Text] [Related]  

  • 32. Are rich nations up for drug reform?
    Check E
    Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
    [No Abstract]   [Full Text] [Related]  

  • 33. Public-private partnerships in drug development for underdeveloped countries: an interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division. Interview by Thomasine Kushner.
    Wheeler C
    Camb Q Healthc Ethics; 2003; 12(4):429-33. PubMed ID: 14619375
    [No Abstract]   [Full Text] [Related]  

  • 34. The corporate social responsibility of the pharmaceutical industry: idealism without illusion and realism without resignation.
    Leisinger KM
    Bus Ethics Q; 2005 Oct; 15(4):577-94. PubMed ID: 16358443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomics knowledge and equity: a global public goods perspective of the patent system.
    Smith RD; Thorsteinsdóttir H; Daar AS; Gold ER; Singers PA
    Bull World Health Organ; 2004 May; 82(5):385-9. PubMed ID: 15298230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast healthcare and cancer control in limited-resource countries: a framework for change.
    Anderson BO
    Nat Clin Pract Oncol; 2006 Jan; 3(1):4-5. PubMed ID: 16407859
    [No Abstract]   [Full Text] [Related]  

  • 37. How should the benefits of bioprospecting be shared?
    Millum J
    Hastings Cent Rep; 2010; 40(1):24-33. PubMed ID: 20169653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Health Impact Fund: boosting pharmaceutical innovation without obstructing free access.
    Pogge T
    Camb Q Healthc Ethics; 2009; 18(1):78-86. PubMed ID: 19091149
    [No Abstract]   [Full Text] [Related]  

  • 39. From quid pro quo to quid pro bono: reshaping the influence of industry on health care epidemiologists.
    Kirkland KB
    Clin Infect Dis; 2010 Jan; 50(1):93-7. PubMed ID: 19951230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The costs of coronavirus vaccines and their pricing.
    Light DW; Lexchin J
    J R Soc Med; 2021 Nov; 114(11):502-504. PubMed ID: 34732097
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.